ROME: Nordic Nanovector ASA (OSE:NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, will announce its third quarter 2015 results, 21 October 2015.
A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CEST at:
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2015 from 7:00 am CEST the same day.
Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over USD 12 billion by 2018.
Betalutin™ comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium- 177). It has shown promising efficacy and a favourable safety profile in a Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at rapidly developing Betalutin™ for the treatment of major types of NHL with first approval anticipated by the end of 2018.
